Long-Term Efficacy of Memantine in Parkinson’s Disease Dementia: An 18-Month Prospective Perfusion Single Photon Emission Computed Tomography Preliminary Study
1
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background and PurposeAlthough the treatment efficacy of memantine in Parkinson’s disease dementia (PDD) has been reported after several weeks of administration, the long-term effects on brain perfusion and clinical symptoms remain unclear. The current study aimed to follow-up PDD patients after 18 months of memantine treatment using 99mTc hexamethylpropylene amine oxime single photon emission computed tomography (SPECT). MethodsA total of 15 patients with PDD and 11 healthy participants were recruited into this study and they were assessed with brain SPECT, Mini-Mental State Examination (MMSE), Clinical Dementia Rating (CDR), Global Deterioration Scale (GDS), and Neuropsychiatric Inventory (NPI). Differences in regional cerebral blood flow (rCBF) between the two groups were evaluated at baseline. After 18 months of memantine administration, changes in brain perfusion, severity of dementia, cognition, and neuropsychiatric disturbances were examined in the patients with PDD. ResultsThe PDD group showed hypoperfusion in most of the cortical, subcortical, and cerebellar areas compared to healthy controls at baseline. At the follow-up, changes in rCBF, CDR (p=0.32), sum of box of CDR (p=0.49), MMSE (p=0.61), GDS (p=0.79), and NPI (p=0.23) were not significant in the PDD patients. ConclusionsOur findings implicate that memantine may delay the progression of brain perfusion deficits and clinical symptoms of PDD in the long term.
Abstract
Background and PurposeAlthough the treatment efficacy of memantine in Parkinson’s disease dementia (PDD) has been reported after several weeks of administration, the long-term effects on brain perfusion and clinical symptoms remain unclear. The current study aimed to follow-up PDD patients after 18 months of memantine treatment using 99mTc hexamethylpropylene amine oxime single photon emission computed tomography (SPECT). MethodsA total of 15 patients with PDD and 11 healthy participants were recruited into this study and they were assessed with brain SPECT, Mini-Mental State Examination (MMSE), Clinical Dementia Rating (CDR), Global Deterioration Scale (GDS), and Neuropsychiatric Inventory (NPI). Differences in regional cerebral blood flow (rCBF) between the two groups were evaluated at baseline. After 18 months of memantine administration, changes in brain perfusion, severity of dementia, cognition, and neuropsychiatric disturbances were examined in the patients with PDD. ResultsThe PDD group showed hypoperfusion in most of the cortical, subcortical, and cerebellar areas compared to healthy controls at baseline. At the follow-up, changes in rCBF, CDR (p=0.32), sum of box of CDR (p=0.49), MMSE (p=0.61), GDS (p=0.79), and NPI (p=0.23) were not significant in the PDD patients. ConclusionsOur findings implicate that memantine may delay the progression of brain perfusion deficits and clinical symptoms of PDD in the long term.
참고문헌 (31)
- Docherty MJ, "Parkinson’s disease dementia", Curr Neurol Neurosci Rep, 10, pp.292~298 (2010)
- Aarsland D, "Risk of dementia in Parkinson’s disease : a communitybased, prospective study", Neurology, 56, pp.730~736 (2001)
- Schrag A, "How does Parkinson’s disease affect quality of life? A comparison with quality of life in the general population", Mov Disord, 15, pp.1112~1118 (2000)
- Schrag A, "Caregiverburden in parkinson’s disease is closely associated with psychiatric symptoms, falls, and disability", Parkinsonism Relat Disord, 12, pp.35~41 (2006)
- Aarsland D, "Neuropsychiatric symptoms in patients with Parkinson’s disease and dementia : frequency, profile and associated care giver stress", J Neurol Neurosurg Psychiatry, 78, pp.36~42 (2007)
- Bohnen NI, "Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease : an in vivo positron emission tomographic study", Arch Neurol, 60, pp.1745~1748 (2003)
- Emre M, "Rivastigmine for dementia associated with Parkinson’s disease", N Engl J Med, 351, pp.2509~2518 (2004)
- Dalfó E, "Abnormal metabotropic glutamate receptor expression and signaling in the cerebral cortex in diffuse Lewy body disease is associated with irregular alpha-synuclein", phospholipase C(PLCbeta1)interactions, 2004, pp.14, 388~398
- Aarsland D, "Memantine in patients with Parkinson’s disease dementia or dementia with Lewy bodies : a double-blind, placebo-controlled, multicentre trial", Lancet Neurol, 8, pp.613~618 (2009)
- Emre M, "Memantine for patients with Parkinson’s disease dementia or dementia with Lewy bodies : a randomised, double-blind, placebo-controlled trial", Lancet Neurol, 9, pp.969~977 (2010)
- Wesnes KA, "Memantine improves attention and episodic memory in Parkinson’s disease dementia and dementia with Lewy bodies", Int J Geriatr Psychiatry, 30, pp.46~54 (2015)
- Song IU, "Efficacy of an NMDA receptor antagonist for Parkinson’s disease dementia : a brain perfusion SPECT study", Int J Imaging Syst Technol, 21, pp.326~331 (2014)
- American Psychiatric Association, "Diagnostic and statistical manual of mental disorders", American Psychiatric Association, ~ (2000)
- Hoehn MM, "Parkinsonism : onset, progression and mortality", Neurology, 17, pp.427~442 (1967)
- Morris JC, "The Consortium to Establish a Registry for Alzheimer’s Disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer’s disease", Neurology, 39, pp.1159~1165 (1989)
- 최성혜, "한국판 Global Deterioration Scale의 타당도", 대한신경과학회지, 20(6), pp.612~617 (2002), 대한신경과학회
- Kang Y, "A validity study on the Korean Mini-Mental State Examination(K-MMSE)in dementia patients", J Korean Neurol Assoc, 15, pp.300~308 (1997)
- Choi SH, "The Korean version of the neuropsychiatric inventory : a scoring tool for neuropsychiatric disturbance in dementia patients", J Korean Med Sci, 15, pp.609~615 (2000)
- Yakushev I, "SPM-based count normalization provides excellent discrimination of mild Alzheimer’s disease and amnestic mild cognitive impairment from healthy aging", Neuroimage, 44, pp.43~50 (2009)
- Borghammer P, "Data-driven intensity normalization of PET group comparison studies is superior to global mean normalization", Neuroimage, 46, pp.981~988 (2009)
- Antonini A, "Perfusion ECD", SPECT in the characterization of cognitive deficits in Parkinson’s disease, 2001, pp.22, 45~46
- Yong SW, "A comparison of cerebral glucose metabolism in Parkinson’s disease, Parkinson’s disease dementia and dementia with Lewy bodies", Eur J Neurol, 14, pp.1357~1362 (2007)
- Firbank MJ, "Regional cerebral blood flow in Parkinson’s disease with and without dementia", Neuroimage, 20, pp.1309~1319 (2003)
- Le Heron CJ, "Comparing cerebral perfusion in Alzheimer’s disease and Parkinson’s disease dementia : an ASL-MRI study", J Cereb Blood Flow Metab, 34, pp.964~970 (2014)
- Marvanová M, "The neuroprotective agent memantine induces brain-derived neurotrophic factor and trkB receptor expression in rat brain", Mol Cell Neurosci, 18, pp.247~258 (2001)
- Howells DW, "Reduced BDNF mRNA expression in the Parkinson’s disease substantia nigra", Exp Neurol, 166, pp.127~135 (2000)
- Nagatsu T, "Changes in cytokines and neurotrophins in Parkinson’s disease", J Neural Transm Suppl, (60), pp.277~290 (2000)
- Phillips HS, "BDNF mRNA is decreased in the hippocampus of individuals with Alzheimer’s disease", Neuron, 7, pp.695~702 (1991)
- Siegel GJ, "Neurotrophic factors in Alzheimer’s and Parkinson’s disease brain", Brain Res Brain Res Rev, 33, pp.199~227 (2000)
- Altar CA, "Brain-derived neurotrophic factor augments rotational behavior and nigrostriatal dopamine turnover in vivo", Proc Natl Acad Sci U S A, 89, pp.11347~11351 (1992)
- Shults CW, "BDNF attenuates the effects of intrastriatal injection of 6-hydroxydopamine", Neuroreport, 6, pp.1109~1112 (1995)